That's the question we need to ask. There's more to this story and I'm afraid the rest will come from Teva and/or the FDA. I would expect this PR after T-Lovenox approval. Regardless this company has an exciting future.
teva has made comments to the effect that they can meet the five criteria laid out by the FDA. MNTA may feel that the only way to possibly meet those criteria is to utilize analytics that are covered by their patents. so while they clearly can't know specifically if teva can back up their comments, mnta may construe the comments at face value and with the lawsuit force teva's hand to disclose whether or not they in fact have used sophisticated analytics (that violate patents), or they are just talking trash about meeting the criteria in which case the lawsuit gets thrown out but the public finally learns teva is full of shit just my guess
Market Data 
Markets 
AI
